Stocks Overview

LAST PRICE
27.7500
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
27.5100/ 1
Ask / Lots
30.0000/ 2
Open / Previous Close
--- / 27.7500
Day Range
---
52 Week Range
Low 14.2200
High 47.9700
Volume
204
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Tuesday's close: 27.83
Time	Volume	SYRE
09:32 ET	2580	28.22
09:33 ET	300	28.225
09:35 ET	2100	28.14
09:37 ET	992	27.85
09:39 ET	600	27.98
09:42 ET	200	27.99
09:46 ET	200	28.01
09:48 ET	1400	27.9
09:50 ET	1279	27.82
09:51 ET	1992	27.72
09:53 ET	1500	27.8
09:55 ET	900	27.79
10:00 ET	800	27.755
10:02 ET	400	27.79
10:04 ET	3450	27.81
10:06 ET	1507	27.57
10:08 ET	1100	27.535
10:09 ET	894	27.66
10:11 ET	1203	27.68
10:13 ET	200	27.81
10:15 ET	314	27.695
10:18 ET	300	27.78
10:20 ET	1597	27.725
10:22 ET	100	27.75
10:24 ET	886	27.645
10:26 ET	200	27.64
10:27 ET	100	27.53
10:29 ET	796	27.52
10:31 ET	400	27.5
10:33 ET	100	27.41
10:36 ET	480	27.395
10:38 ET	300	27.415
10:42 ET	100	27.345
10:44 ET	100	27.345
10:47 ET	300	27.315
10:49 ET	2000	27.23
10:54 ET	200	27.31
10:56 ET	5400	27.45
10:58 ET	335	27.5299
11:00 ET	825	27.45
11:02 ET	3288	27.465
11:03 ET	100	27.58
11:05 ET	200	27.535
11:07 ET	1300	27.585
11:09 ET	200	27.59
11:14 ET	1006	27.625
11:16 ET	2200	27.5
11:18 ET	1509	27.69
11:20 ET	1448	27.7
11:21 ET	1700	27.62
11:23 ET	2091	27.64
11:25 ET	700	27.635
11:27 ET	1350	27.5
11:30 ET	1600	27.575
11:32 ET	800	27.47
11:34 ET	700	27.58
11:36 ET	700	27.55
11:38 ET	300	27.65
11:39 ET	1300	27.615
11:41 ET	1200	27.717
11:43 ET	1950	27.77
11:45 ET	1500	27.72
11:48 ET	5300	27.65
11:50 ET	1200	27.65
11:52 ET	832	27.65
11:54 ET	100	27.675
11:57 ET	300	27.62
11:59 ET	600	27.57
12:01 ET	500	27.46
12:03 ET	710	27.4
12:06 ET	530	27.46
12:10 ET	434	27.36
12:12 ET	2123	27.44
12:14 ET	200	27.445
12:15 ET	1800	27.58
12:17 ET	908	27.56
12:19 ET	344	27.64
12:21 ET	400	27.595
12:24 ET	1241	27.65
12:26 ET	560	27.65
12:28 ET	600	27.65
12:30 ET	600	27.62
12:32 ET	1300	27.595
12:33 ET	1600	27.61
12:35 ET	200	27.64
12:39 ET	100	27.61
12:42 ET	200	27.61
12:44 ET	200	27.65
12:46 ET	500	27.61
12:48 ET	1254	27.53
12:50 ET	400	27.61
12:51 ET	100	27.575
12:55 ET	200	27.6
12:57 ET	400	27.61
01:00 ET	300	27.618
01:02 ET	434	27.64
01:04 ET	100	27.63
01:06 ET	700	27.565
01:11 ET	400	27.515
01:13 ET	100	27.49
01:15 ET	300	27.485
01:18 ET	900	27.505
01:20 ET	1200	27.455
01:22 ET	729	27.4875
01:24 ET	500	27.48
01:26 ET	4131	27.355
01:27 ET	100	27.41
01:29 ET	1700	27.405
01:31 ET	404	27.38
01:33 ET	626	27.41
01:36 ET	200	27.4
01:38 ET	2124	27.345
01:40 ET	1100	27.39
01:42 ET	1619	27.34
01:45 ET	200	27.345
01:47 ET	800	27.33
01:49 ET	220	27.35
01:51 ET	1131	27.36
01:54 ET	100	27.345
01:56 ET	2098	27.4
01:58 ET	551	27.43
02:00 ET	1000	27.43
02:03 ET	200	27.4
02:05 ET	100	27.4
02:07 ET	400	27.37
02:09 ET	676	27.36
02:12 ET	400	27.3235
02:14 ET	864	27.365
02:16 ET	1200	27.32
02:18 ET	200	27.335
02:20 ET	200	27.37
02:21 ET	2336	27.45
02:23 ET	2067	27.56
02:25 ET	2200	27.57
02:27 ET	300	27.595
02:30 ET	1548	27.55
02:32 ET	100	27.56
02:34 ET	100	27.5
02:36 ET	915	27.56
02:38 ET	1675	27.52
02:39 ET	900	27.515
02:41 ET	500	27.54
02:43 ET	747	27.495
02:45 ET	920	27.55
02:48 ET	900	27.55
02:50 ET	1500	27.59
02:52 ET	600	27.575
02:54 ET	200	27.6
02:56 ET	1504	27.6
02:57 ET	400	27.6
02:59 ET	2303	27.6
03:01 ET	1449	27.55
03:03 ET	1400	27.52
03:06 ET	989	27.485
03:08 ET	400	27.5
03:12 ET	1762	27.55
03:14 ET	3145	27.57
03:15 ET	700	27.61
03:17 ET	100	27.59
03:19 ET	100	27.615
03:21 ET	3105	27.57
03:24 ET	2072	27.53
03:26 ET	300	27.535
03:28 ET	437	27.53
03:30 ET	1200	27.55
03:32 ET	900	27.55
03:33 ET	820	27.56
03:35 ET	1864	27.59
03:37 ET	9889	27.53
03:39 ET	12628	27.525
03:42 ET	8976	27.7
03:44 ET	5017	27.74
03:46 ET	1299	27.68
03:48 ET	2000	27.705
03:50 ET	1076	27.75
03:51 ET	5247	27.79
03:53 ET	5681	27.97
03:55 ET	7823	27.94
03:57 ET	13231	27.975
04:00 ET	104320	27.75

Data delayed at least 15 minutes.

Yesterday
- Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
Nov 27, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 12:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
  12:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
- Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation, from 10:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  10:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 26, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 7:24PM ET on Tuesday Nov 26, 2024 by Dow Jones
  7:24PM ET on Tuesday Nov 26, 2024 by Dow Jones
- Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect, from 10:01AM ET on Tuesday Nov 26, 2024 by Dow Jones
  10:01AM ET on Tuesday Nov 26, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesSYRE Spyre Therapeutics Inc	1.6B	-3.7x	---
United StatesNMRA Neumora Therapeutics Inc	1.6B	-5.5x	---
United StatesVRDN Viridian Therapeutics Inc	1.7B	-5.1x	---
United StatesPRAX Praxis Precision Medicines Inc	1.5B	-7.7x	---
United StatesSPRY ARS Pharmaceuticals Inc	1.4B	-28.6x	---
United StatesSNDX Syndax Pharmaceuticals Inc	1.4B	-4.5x	---
As of 2024-11-29

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Contact Information

Headquarters: 221 Crescent Street, Suite 105WALTHAM, MA, United States 02453
Phone: 617-651-5940
Fax: 302-636-5454

Executives

Chief Executive Officer, Director: Cameron Turtle
Chief Financial Officer: Scott Burrows
Chief Medical Officer: Sheldon Sloan
Chief Legal Officer, Corporate Secretary: Heidy King-Jones
Director: Mark Mckenna

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$1.6B
Revenue (TTM)	$0.00
Shares Outstanding	58.7M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	2.82
EPS	$-7.44
Book Value	$7.45
P/E Ratio	-3.7x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Spyre Therapeutics Inc
NASDAQ:SYREUnited States

Search Criteria

Charts

Recent News

Yesterday

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation, from 23 hours ago by Dow Jones

Nov 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 12:01PM ET on Wednesday Nov 27, 2024 by Dow Jones

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation, from 10:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 26, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE, from 7:24PM ET on Tuesday Nov 26, 2024 by Dow Jones

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect, from 10:01AM ET on Tuesday Nov 26, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar